Clinical and Translational Research in Cancer
Lines of Research
01.Clinical-translational research in breast, prostate, gynecological, digestive, and germ cell cancers
02.Translational research in the identification of epigenetic/genetic markers in early stages of cancer
03.Research on the use of new diagnostic techniques (liquid biopsy, etc.) and markers
04.Research on the relationship between the microbiota and cancer
05.Research on real-world data real world data
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
INMACULADA RAMOS GARCIA – ENSAYO CLINICO COMERCIAL – GENMAB A/S
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors
JAVIER GARCÍA CORBACHO – ENSAYO CLINICO COMERCIAL – ABBVIE DEUTSCHLAND GMBH & CON K. G
2023-12144 Estudio observacional, internacional, retrospectivo de revisión de historias clínicas, para describir las características, patrones de tratamiento y resultados clínicos en los pacientes tratados con selpercatinib dentro de un Programa de Acceso Temprano en España y Portugal (Estudio SELPIBER).
ANDRES MESAS RUIZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTO – LILLY, S.A.
“Estudio fase 1/2 de BMS-986449 en monoterapia y en combinación con Nivolumab en pacientes con tumores sólidos avanzados”
JAVIER GARCÍA CORBACHO – ENSAYO CLÍNICO CON MEDICAMENTOS – BRISTOL MYERS SQUIBB COMPANY
“Estudio fase 1/2 de BMS-986340 en monoterapia y en combinación con Nivolumab o Docetaxel en pacientes con tumores sólidos avanzados”
JAVIER GARCÍA CORBACHO – ENSAYO CLÍNICO CON MEDICAMENTOS – BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
“ESTUDIO EN FASE III, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE INAVOLISIB MÁS FULVESTRANT FRENTE A ALPELISIB MÁS FULVESTRANT EN PACIENTES CON CÁNCER DE MAMA CON RECEPTOR HORMONAL POSITIVO, HER2 NEGATIVO Y PIK3CA MUTADO, LOCALMENTE AVANZADO O METASTÁSICO QUE EXPERIMENTARON PROGRESIÓN DURANTE O DESPUÉS DEL TRATAMIENTO COMBINADO CON INHIBIDOR DE CDK4/6 Y TRATAMIENTO ENDOCRINO”
ANA GODOY ORTIZ – ENSAYO CLÍNICO CON MEDICAMENTOS – ROCHE FARMA, S.A.
“Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante”. Estudio OLYMPIA.
ANTONIA MÁRQUEZ ARAGONÉS – ENSAYO CLINICO COMERCIAL – ASTRAZENECA AB
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon, J; Mendez, M; Gomez, S; Garcia, JF; Martin, P; Bellas, C; Pedrosa, L; Rodriguez-Pinilla, SM; Camacho, FI; Quero, C; Perez-Callejo, D; Rueda, A; Llanos, M; Gomez-Codina, J; Piris, MA; Montes-Moreno, S; Barcena, C; Rodriguez-Abreu, D; Menarguez, J; De la Cruz-Merino, L; Monsalvo, S; Parejo, C; Royuela, A; Kwee, I; Cascione, L; Arribas, A; Bertoni, F; Mollejo, M; Provencio, M; Sanchez-Beato, M – 2019
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J; Ramos, I; Trigo, JM; Palka, M; Gomez-Rueda, A; Jantus-Lewintre, E; Camps, C; Isla, D; Iranzo, P; Ponce-Aix, S; Garcia-Campelo, R; Provencio, M; Franco, F; Bernabe, R; Juan-Vidal, O; Felip, E; de Castro, J; Sanchez-Torres, JM; Faul, I; Lanman, RB; Garrido, P; Paz-Ares, L – 2019
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Godoy-Ortiz, A; Sanchez-Munoz, A; Parrado, MRC; Alvarez, M; Ribelles, N; Dominguez, AR; Alba, E – 2019
18FDG PET/CT & arterial inflammation: predicting cardiovascular events in lung cancer.
Garcia, ACV; Cardo, AG; Hidalgo, CM; Palomo, L; Lillo, E; Espildora, J; Trigo, JM; Chaparro, MAS; Valdivielso, P – 2019
Gender-Related Differences on Polyamine Metabolome in Liquid Biopsies by a Simple and Sensitive Two-Step Liquid-Liquid Extraction and LC-MS/MS
Samarra, Iris; Ramos-Molina, Bruno; Queipo-Ortuno, M Isabel; Tinahones, Francisco J; Arola, Lluis; Delpino-Rius, Antoni; Herrero, Pol; Canela, Nuria – 2019
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data,
Diaz-Redondo, T; Lavado-Valenzuela, R; Jimenez, B; Pascual, T; Galvez, F; Falcon, A; Alamo, MD; Morales, C; Amerigo, M; Pascual, J; Sanchez-Munoz, A; Gonzalez-Guerrero, M; Vicioso, L; Laborda, A; Ortega, MV; Perez, L; Fernandez-Martinez, A; Chic, N; Jerez, JM; Alvarez, M; Prat, A; Ribelles, N; Alba, E – 2019
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Vivancos, A; Aranda, E; Benavides, M; Elez, E; Gomez-Espana, MA; Toledano, M; Alvarez, M; Parrado, MRC; Garcia-Barberan, V; Diaz-Rubio, E – 2019
VIGLA-M: visual gene expression data analytics.
Navas-Delgado, I; Garcia-Nieto, J; Lopez-Camacho, E; Rybinski, M; Lavado, R; Guerrero, MAB; Aldana-Montes, JF – 2019
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Mendez, M; Torrente, M; Sanchez-Beato, M; Gonzalez-Rincon, J; Royuela, A; Gomez-Codina, J; de la Cruz-Merino, L; Rueda, A; Llanos, M; Quero, C; Rodriguez-Abreu, D; Guma, J; Monsalvo, S; Sabin, P; Provencio, M – 2019
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).
Lopez-Tarruella, Sara; Escudero, M J; Pollan, Marina; Martin, Miguel; Jara, Carlos; Bermejo, Begona; Guerrero-Zotano, Angel; Garcia-Saenz, Jose; Santaballa, Ana; Alba, Emilio; Andres, Raquel; Martinez, Purificacion; Calvo, Lourdes; Fernandez, Antonio; Batista, Norberto; Llombart-Cussac, Antonio; Anton, Antonio; Lahuerta, Ainhara; de la Haba, Juan; Lopez-Vega, Jose Manuel; Carrasco, E – 2019
Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy
Zapata, I; Alvarez, M; Hidalgo, R; Pajares, B; Garcia-Anaya, MJ; Toledo, MD; Trigo, JM; Lupianez-Perez, Y; Medina, JA; Gomez-Millan, JJ – 2019
Altered Adipose Tissue DNA Methylation Status in Metabolic Syndrome: Relationships Between Global DNA Methylation and Specific Methylation at Adipogenic, Lipid Metabolism and Inflammatory Candidate Genes and Metabolic Variables
Castellano-Castillo, D; Moreno-Indias, I; Sanchez-Alcoholado, L; Ramos-Molina, B; Alcaide-Torres, J; Morcillo, S; Ocana-Wilhelmi, L; Tinahones, F; Queipo-Ortuno, MI; Cardona, F – 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; Alfonso, PG; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E – 2019
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Rodriguez, BJ; Cordoba, GD; Aranda, AG; Alvarez, M; Vicioso, L; Perez, CL; Hernando, C; Bermejo, B; Parreno, AJ; Lluch, A; Ryder, MB; Jones, FS; Fredebohm, J; Holtrup, F; Queipo-Ortuno, MI; Alba, E – 2019
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Ocana, A; Gil-Martin, M; Antolin, S; Atienza, M; Montano, A; Ribelles, N; Urruticoechea, A; Falcon, A; Pernas, S; Orlando, J; Montero, JC; Escudero, MJ; Benito, S; Caballero, R; Carrasco, E; Rojo, F; Pandiella, A; Ruiz-Borrego, M – 2019
Effects of SHBG rs1799941 Polymorphism on Free Testosterone Levels and Hypogonadism Risk in Young Non-Diabetic Obese Males
Castellano-Castillo, D; Royo, JL; Martinez-Escribano, A; Sanchez-Alcoholado, L; Molina-Vega, M; Queipo-Ortuno, MI; Ruiz-Galdon, M; Alvarez-Millan, JJ; Cabezas-Sanchez, P; Reyes-Engel, A; Tinahones, FJ; Cardona, F; Fernandez-Garcia, JC – 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Dieras, V; Bonnefoi, H; Alba, E; Awada, A; Coudert, B; Pivot, X; Gligorov, J; Jager, A; Zambelli, S; Lindeman, GJ; Charpentier, E; Emmons, GT; Garcia-Ribas, I; Paridaens, R; Verweij, J – 2019
Type 2 Diabetes Is Associated with a Different Pattern of Serum Polyamines: A Case-Control Study from the PREDIMED-Plus Trial
Fernandez-Garcia, JC; Delpino-Rius, A; Samarra, I; Castellano-Castillo, D; Munoz-Garach, A; Bernal-Lopez, MR; Queipo-Ortuno, MI; Cardona, F; Ramos-Molina, B; Tinahones, FJ – 2019
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM. – 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
Bauer, TM; Besse, B; Martinez-Marti, A; Trigo, JM; Moreno, V; Garrido, P; Ferron-Brady, G; Wu, YH; Park, J; Collingwood, T; Kruger, RG; Mohammad, HP; Ballas, MS; Dhar, A; Govindan, R – 2019
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
-
Investigador/a SéniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a Asistencial Colaborador/aSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a posdoctorales y/o juniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as predoctorales y/o formaciónSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staffSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.